NCT07166419 - Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Chronic Myeloid Leukemia, BCR-ABL1 PositiveRecurrent Indolent Non-Hodgkin LymphomaRecurrent Lymphoblastic LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Chronic Myeloid Leukemia, BCR-ABL1 PositiveRefractory Indolent Non-Hodgkin LymphomaRefractory Lymphoblastic LymphomaRefractory Non-Hodgkin LymphomaRefractory Transformed Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

Autologous Anti-CD19/CD20/CD22 CAR T-cells

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and aspiration

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography Test

Undergo echocardiography

DRUG

Fludarabine

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

PROCEDURE

Pheresis

Undergo apheresis

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

Ohio State University Comprehensive Cancer Center

OTHER